Please provide your email address to receive an email when new articles are posted on . Corneal tissue addition keratoplasty, or CTAK, is a novel intrastromal lamellar keratoplasty technique for the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Epion Therapeutics has initiated its phase 3 Apricity ...

BURLINGTON, Mass.--(BUSINESS WIRE)--Epion Therapeutics (Epion) announced the commencement of its Phase 3 Apricity trials for EpiSmart™, the company’s minimally-invasive keratoconus therapy. This marks ...

Keratoconus is a progressive eye condition that affects the shape and clarity of the cornea, often beginning in the teenage years or early adulthood. As the cornea thins and bulges into a cone-like ...

On Monday, Glaukos Corporation (NYSE:GKOS) received the “Day 74” notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for ...

HealthDay News — For patients aged 5 to 25 years, allergic conjunctivitis is associated with an increased risk for keratoconus and increased corneal diagnostic procedures, according to a study ...

Add Yahoo as a preferred source to see more of our stories on Google. The US Food and Drug Administration (FDA) has approved Glaukos Corporation’s Epioxa, offering patients living with a rare corneal ...

Two surgical procedures have been described for ICRS implantation: the mechanical method and the femtolaser method. The use of femtolaser for ICRS tunnel creation was widely accepted after FDA ...

SALT LAKE CITY--(BUSINESS WIRE)--iVeena Delivery Systems Inc. (“iVeena”), a clinical stage biopharmaceutical company with developmental products in keratoconus and pediatric myopia, has entered into a ...

The average per-person inflation-adjusted lifetime cost of keratoconus treatment in 2019 was nearly $29,000, with a cumulative economic burden of $3.8 billion, a large retrospective cohort study ...